Form 6-K GLAXOSMITHKLINE PLC For: Jan 19
Tweet
Share
E-mail
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
period ending 19 January
2017
GlaxoSmithKline plc
(Name
of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form 40-F
Form
20-F x Form 40-F
--
Indicate
by check mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information
to the Commission pursuant to Rule 12g3-2(b) under the
Securities
Exchange Act of 1934.
Yes
No x
Issued:
Thursday 19 January 2017, London UK - LSE Announcement
Luke Miels appointed President, Global Pharmaceuticals,
GSK
GlaxoSmithKline
plc (LSE/NYSE: GSK) today announced that Luke Miels has been
appointed President, Global Pharmaceuticals, GSK. He will be
responsible for a portfolio of medicines and vaccines with annual
sales of more than £15 billion and operations in over 100
markets.
Luke
will report to Emma Walmsley, who is currently CEO Designate and
will become CEO of GSK in April 2017. His start date will be
announced in due course.
Luke is
currently Executive Vice President (EVP) of AstraZeneca's European
business and was previously EVP, Global Product and Portfolio
Strategy, Global Medical Affairs and Corporate
Affairs.
Commenting on the appointment, Emma Walmsley said: "Luke brings a
combination of excellent R&D insight and a strong track record
of commercial execution.
"We are
now entering a critical period of commercialisation for our new
pharmaceutical products and, over the next two to three years, we
have important data to come on our early-stage pipeline. Luke will
bring a strong new voice to the decisions and choices we will have
to make for our Pharmaceuticals business. I am delighted he has
agreed to join GSK and look forward to welcoming him to the
executive team."
Over
the course of his career, Luke has built highly effective strategic
partnerships between R&D and the relevant commercial
organisations to develop superior portfolio and product franchises
at AstraZeneca, Roche and Sanofi-Aventis. He is known for being
competitive and strongly focussing on the interests of
patients.
Luke
has significant international experience having worked and lived in
the US, China, Singapore, the UK and continental
Europe.
At
AstraZeneca, Luke has helped strengthen the company's product
portfolio, launching Tagrisso in the US, improving growth of the
cardiovascular and metabolic portfolios, notably Brilinta, and
through business development with investments in companies such as
Acerta Pharma and the acquisition of ZS Pharma.
Luke
joined AstraZeneca from Roche, where he was Regional Vice President
Asia Pacific for the Pharmaceuticals Division. Before then, Luke
held roles of increasing seniority at Sanofi-Aventis, including
positions in Asia Pacific and the US. He also co-led the US
integration of Sanofi and Aventis.
Luke
began his career in 1995 as a Sales Representative and Product
Manager with AstraZeneca in Australia. He holds a BSc in biology
from Flinders University in Adelaide and an MBA from the Macquarie
University, Sydney.
-Ends-
GSK - one of
the world's leading research-based pharmaceutical and healthcare
companies - is committed to improving the quality of human life by
enabling people to do more, feel better and live longer. For
further information please visit www.gsk.com.
|
GSK enquiries:
|
|
|
|
|
UK
Media enquiries:
|
David
Mawdsley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Simon
Steel
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Anna
Carruth
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
|
|
|
|
US
Media enquiries:
|
Sarah
Alspach
|
+1 202
715 1048
|
(Washington,
DC)
|
|
|
Sarah
Spencer
|
+1 215
751 3335
|
(Philadelphia)
|
|
|
|
|
|
|
Analyst/Investor
enquiries:
|
Sarah
Elton-Farr
|
+44 (0)
20 8047 5557
|
(London)
|
|
|
Tom
Curry
|
+ 1 215
751 5419
|
(Philadelphia)
|
|
|
Gary
Davies
|
+44 (0)
20 8047 5503
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
Inside
information
The
information contained in this announcement is inside information.
If you have any queries on this, then please contact Victoria Whyte
GSK Company Secretary (responsible for arranging the release of
this announcement) at GSK House Brentford, Middlesex, TW8 9GS on
+44 208 047 5000.
|
Cautionary statement regarding forward-looking statementsGSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
'Risk factors' in the company's Annual Report on Form 20-F for
2015.
|
|
Registered in England & Wales:
No. 3888792
|
|
|
|
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
|
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: January
19, 2017
|
|
|
|
|
|
|
By: VICTORIA
WHYTE--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- GSK (GSK) call put ratio 12 calls to 1 put with focus on April weekly (26) 41 calls
- TCTM Filed 2023 Annual Report on Form 20-F
- Portland General Electric declares dividend
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
